Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

Published:2020-05 Issue:5 Volume:22 Page:679-684
ISSN:1525-1578
Container-title:The Journal of Molecular Diagnostics
language:en
Short-container-title:The Journal of Molecular Diagnostics

Author:

Yao Qiumei,Bai Yinlei,Orfao Alberto,Kumar Shaji,Chim Chor S.

Funder

Hong Kong Blood Cancer Foundation

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Molecular Medicine,Pathology and Forensic Medicine

Reference15 articles.

1. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis;Munshi;JAMA Oncol,2017

2. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma;Perrot;Blood,2018

3. Meeting report: advances in minimal residual disease testing in multiple myeloma 2018;Landgren;Adv Cell Gene Ther,2019

4. Standardized minimal residual disease detection by next-generation sequencing in multiple myeloma;Yao;Front Oncol,2019

5. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma;Kumar;Lancet Oncol,2016

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative or digital PCR? A comparative analysis for choosing the optimal one for biosensing applications;TrAC Trends in Analytical Chemistry;2024-05

2. Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM;Bone Marrow Transplantation;2024-02-21

3. A study to identify novel biomarkers associated with multiple myeloma;Siberian journal of oncology;2023-11-16

4. Prognostic Factors in 448 Newly Diagnosed Multiple Myeloma Receiving Bortezomib-based Induction: Impact of ASCT, Transplant Refusal and High-Risk MM;2023-09-08

5. Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes–A feasibility study;PLOS ONE;2023-05-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3